Pharvaris

Research only

PHVS · Tracked drugs and regulatory events

Tracked programs

1 program

on-demand treatment of hereditary angioedema attacks

Publication and retrieval dates are shown separately. Market rules determine which evidence can resolve an outcome.

sponsor-releaseir.pharvaris.com

Sponsor describes an oral small-molecule B2 antagonist, RAPIDe-3 and an April 23, 2027 FDA target.

Registry identifies the associated compound, condition and sponsor; trial completion is separate from FDA action.